Credit Suisse analyst Trung Huynh reiterated an Outperform rating on AstraZeneca (NASDAQ: AZN) noting that he revisited his rating and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE